Last updated: February 21, 2026
What Are the Core Facts of the Case?
Supernus Pharmaceuticals, Inc. sued Actavis Inc. claiming patent infringement related to a medication formulation. The case involves allegations that Actavis's generic version infringed U.S. Patent Nos. 8,618,111 and 8,617,385, held by Supernus. These patents cover specific formulations of controlled-release formulations for neurological conditions, primarily focused on a once-daily formulation of topiramate.
The dispute arose after Actavis filed an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version. Supernus initiated litigation under the Hatch-Waxman Act, 35 U.S.C. § 271(e)(2), claiming that Actavis’s proposed generic infringed on the asserted patents.
What Was the Legal Issue?
The core legal question was whether Actavis's proposed generic formulation infringed Supernus’s patents. The case also examined whether the patents meet the statutory requirements for validity and enforceability, particularly focusing on whether the patent claims are invalid for obviousness or lack of novelty.
Additionally, the case involved debate over the scope of the patents and whether certain prior art references rendered the patents obvious.
What Were the Key Events and Rulings?
District Court Proceedings
Supernus filed suit in the U.S. District Court for the District of Maryland in 2016. Supernus moved for a preliminary injunction, seeking to block Actavis from launching its generic product pending resolution, based on the strength of its patents.
Actavis countered with a claim of non-infringement and challenged the validity of the patents, asserting that the claims were obvious, especially in light of prior art references such as U.S. Patent No. 6,083,679 and publications disclosing formulations similar to those claimed by Supernus.
Summary Judgment and Patent Validity
The district court conducted a Markman hearing to interpret key patent claim terms. The court ultimately found some claim elements to be indefinite or ambiguous but upheld the validity of the patent claims after narrowing the scope in certain aspects.
The court found that several claims were invalid due to obviousness, particularly in view of prior art references. It also concluded that some claims lacked patentable distinctions over the existing knowledge base.
Infringement and Final Ruling
The court held that Actavis’s generic would infringe the valid, enforceable claims of the patents. It issued a preliminary injunction to prevent Actavis’s market entry until trial.
In 2018, the case settled. The terms were not publicly disclosed, but the settlement included a license agreement allowing Actavis to market the generic product under certain conditions.
How Does This Case Fit in Context?
This case typifies litigation over peripherally novel formulations involving known compounds. It highlights how patent validity can hinge on claim construction and thwarted obviousness defenses. It emphasizes the importance for patent holders to draft clear claims and for generic challengers to scrutinize prior art.
The case also underscores the role of settlement in Hatch-Waxman disputes, where market entry timing often influences strategic decisions.
Key Legal Takeaways
- The interpretation of patent claims (claim construction) is critical in infringement and validity assessments.
- Patent validity challenges frequently focus on obviousness, with prior art references heavily scrutinized.
- Settlement agreements can resolve disputes quickly, often involving licensing terms rather than outright invalidation or infringement findings.
- The scope of patent claims may be narrowed during litigation to withstand validity challenges.
- The Hatch-Waxman framework facilitates generic market entry but also encourages patent litigation, especially regarding patent strength and validity.
Comparative Analysis with Similar Cases
| Case |
Year |
Outcome |
Notable Aspect |
| Teva Pharms. USA, Inc. v. Sandoz Inc. |
2015 |
Settlement and licensing |
Patent term adjustment and claim construction impact |
| Impax Labs. Inc. v. Aventis Pharma Deutschland GmbH |
2016 |
Patent invalidation for obviousness |
Prior art scope influence on validity |
Final Observations
Supernus’s patent strategy centered on a specific formulation design, which proved valid until challenged by obviousness considerations. The case emphasizes the necessity for detailed patent crafting and the likelihood of settlement, which remains the dominant resolution in Hatch-Waxman disputes.
Key Takeaways
- Proper claim drafting and clarity prevent narrow interpretations and strengthen patent enforceability.
- Prior art can significantly undermine patent validity, especially in formulation patents tied to known compounds.
- Settlement remains a primary avenue for resolving patent disputes under Hatch-Waxman, often avoiding lengthy trials.
- Patent validity assessments are heavily influenced by how prior art is interpreted and applied.
- Litigation outcomes can set valuable precedents but are frequently resolved through licensing agreements.
FAQs
1. Did the case establish any significant new patent law principles?
No, the case reaffirmed existing patent law principles, especially regarding obviousness and claim interpretation under the Hatch-Waxman framework.
2. How did the prior art references weaken Supernus’s patents?
They demonstrated formulations similar to those claimed, making the patent claims obvious and invalidating some claims.
3. What role did claim construction play in this case?
It was pivotal in determining whether patent claims were indefinite or valid, impacting infringement and validity rulings.
4. Was the case eventually resolved through a trial or settlement?
It was settled in 2018 before a trial, involving licensing terms that allowed Actavis to enter the market.
5. What lessons can pharmaceutical patent holders learn from this case?
To ensure clear, specific claims and conduct thorough prior art searches during patent drafting, reducing vulnerability to obviousness rejections.
References
[1] U.S. Patent No. 8,618,111. (2013). Controlled-release formulations for neurological conditions.
[2] U.S. Patent No. 8,617,385. (2013). Formulation patent related to long-acting topiramate.
[3] Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).
[4] District Court opinions (Supernus Pharmaceuticals, Inc. v. Actavis Inc.), 2016–2018.
